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THE USE of gut sterilization in a pro-
tected environment has been under investi-
gation for several years as a means of
reducing infection in patients with cancer
undergoing intensive chemotherapy
(Bodey et al., 1971; Levine et al., 1973;
Yates and Holland, 1973). The possible
effect of the gut sterilizing regimen on the
pharmacokinetics of the cancer chemo-
therapeutic agents being used in these
patients is clearly a matter of some
importance but has not hitherto been
explored. We report observations on the
plasma decay of radioactivity in patients
who received tritium-labelled methotrex-
ate ([3H]MTX) while on such a regimen,
which indicate a possible alteration in the
pharmacokinetics of this drug in these
patients.
Nine patients were studied, each
twice, once before and once during treat-
ment with prophylactic non-absorbable
antibiotics (PNAA). All patients had
small-cell carcinoma of the lung. They
had normal renal and hepatic function,
were free of clinical infections and had had
no prior radio- or chemotherapy. All
gave written informed consent for entry
into the study. Five patients received
oral MTX and 4 received the drug i.v., in
all cases at a dose of 15 mg/M2. For oral
administration, fasting patients received
[3H]MTX (250,aCi) shown to be > 98%
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radiochromatographically pure, mixed
with the clinical dosage form of MTX as a
solution in 100 ml of water. One to two
weeks after commencing treatment with
PNAA, at which time stool cultures were
sterile, the study was repeated. For i.v.
administration patients received the drug
in 10 ml of isotonic saline by rapid
injection into an arm vein (in these cases
blood was collected from the other arm).
For the i.v. administration, 250 pCi of
[3H]MTX sterilized by filtration was
added to the ampoule ofthe clinical dosage
form just prior to injection. Plasma
radioactivity was determined as previously
described (Creaven et al., 1973). All
urine passed in the 72 h after drug admini-
stration was collected as passed, immedi-
ately frozen, and the radioactivity deter-
mined by counting 0KI ml of an appro-
priately diluted sample in the same way
as for plasma. Patients received MTX
twice weekly, chloroethylcyclohexylnitro-
sourea (CCNU) (100 mg/M2 orally every
6 weeks) and cyclophosphamide (1 g/m2
i.v. every 3 weeks). However, the dose of
MTX studied was in each case given by
itself. PNAA consisted of polymyxin B
100 mg, paromomycin 800 mg, mycostatin
suspension 800,000 u, vancomycin 500 mg
and nystatin tablets 3 million u. All
were given 4 x daily orally. Polymyxin
B, vancomycin, nystatin and neomycin
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were used in nasal and oral spray, in
addition to oral administration. Non-
linear least squares regression analysis of
the data was carried out using the
programme MLAB on a DEC system 10
computer (Knott and Reece, 1972; Knott
and Schrager, 1972).
Absorption of MTX after oral dosage,
both before and during treatment with
PNAA, was rapid, the absorptive phase
being complete by 2 h. However, absorp-
tion was markedly depressed during
PNAA treatment; total urinary recovery
of 3H being 75-7 ± 10.6% before PNAA,
and 41-1 + 10-7% during PNAA treat-
ment, in these 5 patients, a difference
significant at the P < 0 001 level. The
post-absorptive plasma decayduringtreat-
ment with PNAA showed an absence of
the long terminal phase half-life in all
cases (Fig. 1). Analysis of the post-
absorptive phase by non-linear least
squares regression showed that before
PNAA treatment it fitted the bi-exponen-
tial equation
Cp =Ae-,x + Be-fl (1)
whereas during PNAA treatment it fitted
the mono-exponential equation
Cp=Ae-t (2)
The parameters derived by fitting the
data to equation (1) and equation (2)
are given in the Table. When the drug
was given i.v., PNAA treatment did not
significantly alter the post-distributional
plasma decay kinetics (Fig. 2, Table).
The half-life of the terminal phase of the
plasma decay was, however, considerably
shorter after i.v. than after oral dosage.
The data presented here indicate a
marked change in the kinetics of plasma
decay of radioactivity following oral
administration of [3H]MTX during gut
sterilization by PNAA. This could be
due to a number of factors, including the
presence of the antibiotics in the gut,
the absence of bacteria, or some effect of
PNAA on the gut. The present results
do not distinguish between these possibili-
ties. A long half-life terminal phase of
the plasma decay of radioactivity follow-
ing [3H]MTX is well known (Henderson,
Adamson and Oliverio, 1965; Huffman et
al., 1973; Leme et al., 1975) and is con-
firmed in the present study. We have
previously suggested that this long half-
life material cannot be MTX itself, since it
behaves kinetically in a way which is
distinct from MTX (Leme et al., 1975) and
have hypothesized that it may be pro-
duced by gut bacteria from MTX excreted
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FiG. 1.-Plasma decay of total radioactivity after a single oral dose of [3H]MTX (15 mg/M2) before
(O OZ) and during (A A) treatment with PNAA. Each value represents the mean from
the observations on 5 patients studied before and during PNAA treatment.
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FIG. 2. Plasma decay of total radioactivity after a single intravenous dose of [3H]MTX (15 mg/Mr2)
before ( n C) and during (A A) PNAA treatment. Each value represents the mean from
observations on 4 patients studied before and during PNAA treatment.
in the bile, and then reabsorbed. In rats
and mice, MTX is degraded by intestinal
bacteria (Zaharko and Oliverio, 1970;
Valerino et al., 1972), and a divergence in
the plasma decay curves of total radio-
activity and unchanged MTX is seen at 6 h
post-infusion of [3H]MTX (Kates and
Tozer, 1973). A change in the metabolism
and excretion of MTX in mice treated
with neomycin and sulphathiazole to
sterilize the gut, has been reported by
Zaharko, Bruckner and Oliverio (1969).
However, if the long half-life material is a
bacterial breakdown product and is absent
during PNAA treatment after oral admini-
stration of[3H]MTXbecauseofthe absence
ofgut bacteria necessary for its formation,
it is difficult to understand why it is not
also absent during PNAA treatment when
the drug is given i.v. Unfortunately, the
very low amounts of radioactivity in the
samples at later times after dosage pre-
cluded chromatographic separation and
isolation ofthis material for identification.
The same difficulty arises if one wishes
to postulate failure of absorption, inter-
fering with enterohepatic recycling, as the
basis for the difference seen in the present
study. The absorption of MTX is im-
paired during PNAA treatment (Table) as
part ofa general malabsorption as we have
noted previously (Cohen et al., 1975).
However, if the change in kinetics were
due to this, one would also expect that it
would be seen with i.v. administration of
the drug. It is hoped to investigate these
questions further by the use of specific
assays for plasma MTX, to compare with
the results given here for total plasma
radioactivity.
Although the cause of the changes in
the kinetics of decay ofradioactivity after
oral [3H]MTX is uncertain, it seems very
likely, from the results presented, that
there are important changes in MTX
kinetics during PNAA treatment. Such
changes would clearly have important
potential implications for the toxicity and
therapeutic efficacy of MTX during gut
sterilization.
We thank Ms D. Alford Hoyt and Ms
T. Gregorio for expert technical assistance
and Ms A. Tvardzik and Ms C. Williams
for assistance with the patient studies.
574MTX DECAY AND GUT STERILIZATION 575
REFERENCES
BODEY, G. P., GEHAN, E. A., FREIREICH, E. J. &
FREI, E., III, (1971) Protected Environment-
Prophylactic Antibiotic Program in the Chemo-
therapy of Acute Leukemia. Am. J. Sci., 262,
138.
COHEN, M. H., CREAVEN, P. J., FOSSIECK, B. E., JR.,
TVARDZIK, A. V. & WILLIAMS, C. L. (1975) Effect
of Prophylactic Broad Spectrum Nonabsorbable
Gastrointestinal Antibiotics (PNAA) on Absorp-
tion of Methotrexate and on other Metabolic
Parameters of Lung Cancer Patients. Proc Am.
Soc. clin. Oncol., 16, 154.
CREAVEN, P. J., HANSEN, H. H., ALFORD, D. A. &
ALLEN, L. M. (1973) Methotrexate in Liver and
Bile after Intravenous Dosage in Man. Br. J.
Cancer, 28, 589.
HENDERSON, E. S., ADAMSON, R. H. & OLIVERIO,
V. T. (1965) The Metabolic Fate of Tritiated
Methotrexate. II. Absorption and Excretion in
Man. Cancer Res., 25, 1018.
HUFFMAN, D. H., WAN, S. H., AZAROFF, D. L. &
HoOGSTRATEN, B. (1973) Pharmacokinetics of
Methotrexate. Clin. Pharmacol. Ther., 14, 572.
KATES, R. E. & TOZER, T. N. (1973) Separation of
Methotrexate and Nonmethotrexate Components
in Rat Plasma (1973). J. Pharm. Sci., 62, 2056.
KNOTT, G. D. & REECE, D. K. (1972) MLAB: A
Civilized Curve Fitting System. Proc. On-Line,
1, 497.
KNOTT. G. D. & SCHRAGER, R. I. (1972) On-Line
Modelling by Curve Fitting. Proc. Siggraph., 6,
138.
LEME, P. R., CREAVEN, P. J., ALLEN, L. M. &
BERMAN, M. (1975) A Kinetic Model for the
Disposition and Metabolism ofModerate and High
Dose Methotrexate in Man. Cancer Chemother.
Rep.,59, 811.
LEVINE, A. S., SIEGEL, S. E., SCHREIBER, A. D.,
HAUSER, J., PREISLER, H., GOLDSTEIN, I. M.,
SEIDLER, F., SIMON, R., PERRY, S., BENNET, J. E.,
& HENDERSON, E. S. (1973) Protected Environ-
ments and Prophylactic Antibiotics. A Pros-
pective Controlled Study of Their Utility in the
Therapy ofAcute Leukemia. New Engl. J. Med.,
288,477.
VALERINO, D. M., JOHNS, D. G., ZAHARKO, D. S. &
OLIVERIO, V. T. (1972) Studies of the Metabolism
of Methotrexate by Intestinal Flora-I. Biochem.
Pharmacol., 21, 821.
YATES, J. W. & HOLLAND, J. F. (1973) A Controlled
Study of Isolation and Endogenous Microbial
Suppression in Acute Myelocytic Leukemia
Patients. Cancer, N.Y., 32, 1490.
ZAHARKO, D. S., BRUCKNER, H. & OLIVE1RIO, V. T.
(1969) Antibiotics Alter Methotrexate Metabolism
and Excretion. Science, N.Y., 166, 887.
ZAHARKO, D. S. & OLIVERIO. V. T. (1970) Reinvesti-
gation of Methotrexate Metabolism in Rodents.
Biochem. Pharmac., 19, 2923.
39